Drugs / Pegylated Recombinant Candida Utilis Uricase
Pegylated Recombinant Candida Utilis Uricase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06629376 | Nov 2023 → Dec 2026 expected | gout | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Recombinant Candida Utilis Uricase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06629376 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated recombinant Candida urate oxidase” NCT06629376 ↗ |
| Route | Intravenous | “intravenous infusion should be administered for at least 2 hours each time” NCT06629376 ↗ |